DaiichiSankyo-logo-1

Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

Recommendation based on DESTINY-Breast03 trial results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced the risk of disease progression or...

SMU-AIA

AIA Singapore and SMU to pilot a new Actuarial Science Work-Study Elective to support nation’s efforts in integrating university students into the wider industry, business and social ecosystem